Overview

The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To assess whether the anti-inflammatory effects of rosiglitazone result in improvements in Rheumatoid Arthritis symptoms in patients for whom their existing Disease Modifying Anti-Rheumatic Drug (DMARD) treatment does not give adequate relief.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Anti-Inflammatory Agents
Rosiglitazone